5cfccf66-7f7d-4385-96c8-8628a3cdbecb
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 58.5051334702259
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.370
- MITOTIC_SPINDLE+0.200
- MYC_TARGETS_V2+0.200
- APICAL_JUNCTION+0.140
- OXIDATIVE_PHOSPHORYLATION+0.130
- P53_PATHWAY+0.110
- ESTROGEN_RESPONSE_EARLY+0.100
- ESTROGEN_RESPONSE_LATE+0.100
- KRAS_SIGNALING_DN+0.100
- XENOBIOTIC_METABOLISM+0.100
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.450
- ANGIOGENESIS-0.420
- ALLOGRAFT_REJECTION-0.410
- INTERFERON_GAMMA_RESPONSE-0.410
- INFLAMMATORY_RESPONSE-0.400
- PROTEIN_SECRETION-0.390
- IL6_JAK_STAT3_SIGNALING-0.350
- INTERFERON_ALPHA_RESPONSE-0.350
- TNFA_SIGNALING_VIA_NFKB-0.340
- KRAS_SIGNALING_UP-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 72c16603-1f6c-479c-8cf0-95d499f328be | — | — | 0.858 |
| 2 | MDT-AP-1134 | Med | Medulloblastoma | 0.827 |
| 3 | 124c158a-8435-4f81-b84e-89ccc4bb53f1 | — | — | 0.825 |
| 4 | DRR168523 | — | — | 0.815 |
| 5 | MDT-AP-0578 | Med | Medulloblastoma | 0.809 |
| 6 | TCGA-56-A4BX-01A-11R-A24H-07 | — | cohortSQ2 | 0.808 |
| 7 | TCGA-B6-A0X0-01A-21R-A115-07 | — | B | 0.796 |
| 8 | TCGA-22-4601-01A-01R-1443-07 | — | cohortSQ2 | 0.793 |
| 9 | 68fda9a5-c6eb-4445-91f7-bd0078080b9d | — | — | 0.791 |
| 10 | MNG857 | — | — | 0.791 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.370 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.200 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.140 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.130 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.110 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.100 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.100 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.090 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.070 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.070 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.050 | Temsirolimus | — uncovered |
| NOTCH_SIGNALING | 0.050 | Inavolisib | — uncovered |
| PEROXISOME | 0.040 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.030 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.030 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.030 | Idelalisib | — uncovered |
| MYOGENESIS | 0.020 | Inavolisib | — uncovered |